ReviewInfection and immunity2025
Review in Infection and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mortality risk of carbapenem-resistant hypervirulentFrontiers in public health · 2025Pooled it
- An overview of innate cellular immune responses against hypervirulentEmerging microbes & infections · 2026Review
- METTL3 Alleviates Liver Abscess by Enhancing Macrophage Efferocytosis via mImmunity, inflammation and disease · 2026Article
- Article
- Biofilm, virulence, and ESBL-mediated resistance: unmaskingMicrobiology spectrum · 2026Article
- HypervirulentInternational journal of surgery case reports · 2026Article
- Antibiotic tolerance coupled with limited benefit from drainage: Clinical challenges inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- TARGETING THE CAPSULE OFbioRxiv : the preprint server for biology · 2026Article
- Phosphorylation Modification Characteristics of Liver Injury-Related Proteins inPathogens (Basel, Switzerland) · 2026Article
- Distinct and shared impacts of virulence plasmids on the phenotype and transcriptome in convergent carbapenem-resistant and hypervirulentMicrobiology spectrum · 2026Article
- Phage-Encoded Depolymerase DepKP144 with Therapeutic Potential Against Both K1- and K2-TypeInternational journal of molecular sciences · 2026Article
- Article
- Emergence of hypervirulent Klebsiella pneumoniae ST111 with a novel virulence plasmid causing pyogenic liver abscess.BMC microbiology · 2026Article
- Molecular and mechanistic insights into the gut-liver axis inInfection and immunity · 2026Review
- <p>Molecular medicine reports · 2026Review
- Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing.Gut pathogens · 2026Article
- Antibiotic resistance profiles and genomic analysis of Klebsiella pneumoniae ST15 with mcr-1 gene isolated from mink in China.BMC veterinary research · 2026Article
- Global perspectives on Klebsiella epidemiology and biology: conference report on the KLEBS 2024 symposium.npj antimicrobials and resistance · 2026Article
- Multiloculated Klebsiella liver abscess successfully treated with early laparoscopic drainage after failed percutaneous drainage: a case report.AME case reports · 2026Article
- Metformin Enhances Macrophage Phagocytosis and Intracellular Clearance of HypervirulentInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Over the past 30 years, a distinct pathotype of hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.